Keywords: pfizer, caduet, reduces, 10-yr, cv, risk, amlodipine
Pfizer's Caduet reduces 10-yr CV risk by 54%
Article | 23 October 2006
Pfizer's Caduet (amlodipine besylate and atorvastatin calcium) may reduce the 10-year risk of having a cardiovascular event 54% in hypertensive patients ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Is failure to adopt business process management putting the pharma industry at risk?
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- New Zealand declines Alexion's funding application for Solaris
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
